Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics


Adial Pharmaceuticals, Inc (ADIL): $4.18

0.08 (+1.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ADIL Stock Price Chart Interactive Chart >

Price chart for ADIL

ADIL Price/Volume Stats

Current price $4.18 52-week high $4.78
Prev. close $4.10 52-week low $1.14
Day low $4.00 Volume 312,922
Day high $4.25 Avg. volume 789,968
50-day MA $3.20 Dividend yield N/A
200-day MA $2.57 Market Cap 84.85M

Adial Pharmaceuticals, Inc (ADIL) Company Bio


Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.


ADIL Latest News Stream


Event/Time News Detail
Loading, please wait...

ADIL Latest Social Stream


Loading social stream, please wait...

View Full ADIL Social Stream

Latest ADIL News From Around the Web

Below are the latest news stories about Adial Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADIL as an investment opportunity.

Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of Directors

HERNDON, Va., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sysorex (OTCQB: SYSX) (“Sysorex” or the “Company”), the preeminent, U.S.-based, publicly traded Ethereum mining and technologies company, today announced that it has elected William B. Stilley, III to the Company’s Board of Directors and as Chair of the Board’s Audit Committee. The Company also expanded the size of its Board to five directors and established its Audit Committee. Mr. Stilley is the Chief Executive Officer of Adial Pharmaceuticals,

Yahoo | September 13, 2021

The Daily Biotech Pulse: MacroGenics'' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA''s FDA Nod

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced completion of patient enrollment in the pivotal phase 3 study of CAN-2409 in prostate cancer) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (announced addition to its board) Caribou Biosciences, Inc. (NASDAQ: CRBU ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Edwards Lifesciences Corporation (NYSE: EW ) Er...

Benzinga | September 8, 2021

Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, will be presenting at the H.C. Wainwright 23 rd Annual Global Investment Conference being held virtually between September 13-15, 2021.

Intrado Digital Media | September 7, 2021

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

ONWARD trial enrollment closed; trial completion expected in Q1 2022 CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302

Wallstreet:Online | August 31, 2021

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

ONWARD trial enrollment closed; trial completion expected in Q1 2022CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302 patients across 25 clinical sites and has now closed enrollment for its ONWARD™ Phase 3 trial evaluating AD04 a

Yahoo | August 31, 2021

Read More 'ADIL' Stories Here

ADIL Price Returns

1-mo 27.05%
3-mo 43.15%
6-mo 64.57%
1-year 221.54%
3-year 43.15%
5-year N/A
YTD 145.88%
2020 -29.46%
2019 -52.93%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7703 seconds.